Cargando…

Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells

Bio-macromolecules have potential applications in cancer treatment due to their high selectivity and efficiency in hitting therapeutic targets. However, poor cell membrane permeability has limited their broad-spectrum application in cancer treatment. The current study developed highly internalizable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Xiaoqian, Xu, Qinzhi, Dong, Bo, Xu, Guili, Qian, Niliang, Yang, Cuima, Li, Hongjie, Chen, Liting, Gao, Xin, Song, Haifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569552/ https://www.ncbi.nlm.nih.gov/pubmed/36233320 http://dx.doi.org/10.3390/ijms231912018

Ejemplares similares

Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses
por: Schaeper, Ute, et al.
Publicado: (2000)

Essential Role of Gab1 for Signaling by the C-Met Receptor in Vivo
por: Sachs, Martin, et al.
Publicado: (2000)

Understanding the mechanism of binding between Gab2 and the C terminal SH3 domain from Grb2
por: Toto, Angelo, et al.
Publicado: (2017)

A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma
por: Chen, Ximin, et al.
Publicado: (2013)

Targeting the Interaction between the SH3 Domain of Grb2 and Gab2
por: Malagrinò, Francesca, et al.
Publicado: (2020)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Met receptor tyrosine kinase signals through a cortactin–Gab1 scaffold complex, to mediate invadopodia
por: Rajadurai, Charles V., et al.
Publicado: (2012)

HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
por: Fan, Gaofeng, et al.
Publicado: (2016)

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma
por: Zuckermann, Marc, et al.
Publicado: (2022)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

Jet/MET + b/c tagging
por: Komaragiri, Jyothsna Rani
Publicado: (2022)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

c-Met and miRs in Cancer
por: Giglio, Simona, et al.
Publicado: (2015)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
por: Caenepeel, Sean, et al.
Publicado: (2017)

Targeting HGF/c-MET Axis in Pancreatic Cancer
por: Pothula, Srinivasa P., et al.
Publicado: (2020)

Computational study on novel natural inhibitors targeting c-MET
por: Hou, Yuanyuan, et al.
Publicado: (2021)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2)
por: Gu, Dong-Hua, et al.
Publicado: (2017)

c-Met: A Promising Therapeutic Target in Bladder Cancer
por: Feng, Yanfei, et al.
Publicado: (2022)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013)

c-Met is essential for wound healing in the skin
por: Chmielowiec, Jolanta, et al.
Publicado: (2007)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

Structural basis of the activation of c-MET receptor
por: Uchikawa, Emiko, et al.
Publicado: (2021)

Gab2 (Grb2-Associated Binder2) Plays a Crucial Role in Inflammatory Signaling and Endothelial Dysfunction
por: Kondreddy, Vijay, et al.
Publicado: (2021)

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
por: Wang, Ying, et al.
Publicado: (2016)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
por: Kang, Chung Hyo, et al.
Publicado: (2021)

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma
por: Gao, Shan, et al.
Publicado: (2022)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
por: Li, Pengyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_runq5co18hbjns90k5e99obr04